Background/objectives: Resilience, the ability to resist or recover from adverse effects of a stressor, is of widespread interest in social, psychologic, biologic, and medical research and particularly salient as the capacity to respond to stressors becomes diminished with aging. To date, research on human resilience responses to and factors influencing these responses has been limited.
Methods: The National Institute on Aging convened a workshop in August 2015 on needs for research to improve measures to predict and assess resilience in human aging. Effects of aging-related factors in impairing homeostatic responses were developed from examples illustrating multiple determinants of clinical resilience outcomes. Research directions were identified by workshop participants.
Results: Research needs identified included expanded uses of clinical data and specimens in predicting or assessing resilience, and contributions from epidemiological studies in identifying long-term predictors. Better measures, including simulation tests, are needed to assess resilience and its determinants. Mechanistic studies should include exploration of influences of biologic aging processes on human resiliencies. Important resource and infrastructure needs include consensus phenotype definitions of specific resiliencies, capacity to link epidemiological and clinical resilience data, sensor technology to capture responses to stressors, better laboratory animal models of human resiliencies, and new analytic methods to understand the effects of multiple determinants of stress responses.
Conclusions: Extending the focus of care and research to improving the capacity to respond to stressors could benefit older adults in promoting a healthier life span.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861884 | PMC |
http://dx.doi.org/10.1093/gerona/glx015 | DOI Listing |
Brain Behav Immun Health
February 2025
Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Objective: To determine whether a panel of immune markers adds significant information to known correlates of risk of dementia and cognitive impairment.
Background: The impact of immune mechanisms on dementia risk is incompletely characterized.
Design/methods: A subsample of the Northern Manhattan Study, a prospective cohort study in the racially/ethnically diverse population of New York City, underwent comprehensive neuropsychological testing up to three times, at approximately 5-year intervals.
Lancet Reg Health Eur
March 2025
Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.
Background: Ultra-processed food (UPF) consumption has been linked with higher risk of mortality. This multi-centre study investigated associations between food intake by degree of processing, using the Nova classification, and all-cause and cause-specific mortality.
Methods: This study analyzed data from the European Prospective Investigation into Cancer and Nutrition.
Front Nutr
January 2025
Aging and Metabolism Research Program, Oklahoma City, OK, United States.
Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables that has demonstrated anti-cancer, anti-microbial and anti-oxidant properties. SFN ameliorates various disease models in rodents (e.g.
View Article and Find Full Text PDFFront Bioeng Biotechnol
January 2025
MGM Centre of Human Movement Science, MGM School of Physiotherapy, MGM Institute of Health Sciences, Navi Mumbai, India.
Purpose: Pelvic and hip motion are pivotal in maintaining postural control and energy efficient gait. An insight into influence of age and gender on the coupled motion of hip and pelvis in gait-cycle will guide clinical rehabilitation strategies and pertinent technology-design for specific age-groups. Therefore, present study evaluated pelvic and hip-joint gait kinematics in healthy females and males across adult-hood.
View Article and Find Full Text PDFCo-existing neuropathological comorbidities have been repeatedly reported to be extremely common in subjects dying with dementia due to Alzheimer disease. As these are likely to be additive to cognitive impairment, and may not be affected by molecularly-specific AD therapeutics, they may cause significant inter-individual response heterogeneity amongst subjects in AD clinical trials. Furthermore, while originally noted for the oldest old, recent reports have now documented high neuropathological comorbidity prevalences in younger old AD subjects, who are more likely to be included in clinical trials.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!